CBT 001Alternative Names: CBT-001
Latest Information Update: 27 Feb 2017
At a glance
- Originator Cidara Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Recurrent pterygium
Most Recent Events
- 16 Feb 2017 Preclinical trials in Recurrent pterygium in USA (Ophthalmic) before February 2017
- 16 Feb 2017 Cloudbreak therapeutics plans a phase II trial for Recurrent pterygium in USA (NCT03049852)